SOURCE: Cutting Edge Information

Cutting Edge Information

September 23, 2015 08:32 ET

Managed Markets Groups Manage US Government Payer Relationships at Majority of Pharmas, According to Cutting Edge Information

RESEARCH TRIANGLE PARK, NC--(Marketwired - September 23, 2015) - In the life sciences industry, managed markets groups at the majority of surveyed companies are the primary function responsible for communicating with government payers. According to pharmaceutical intelligence firm Cutting Edge Information, these groups are typically trained in discussing health economics data or have the flexibility to engage a medical science liaison (MSL) or health outcomes liaison (HOL). As such, managed markets groups are generally the best equipped team to build payer relationships with government contacts.

Among surveyed respondents, managed markets groups at 57% of companies are tasked with communicating with government payers. MSLs are the primary means of communication at 14% of companies. Meanwhile, 29% of survey respondents selected "other" and indicated dedicated reimbursement or market access-related groups that have similar responsibilities to a managed markets group.

"An important aspect of government payer relationship management is frequent contact," said Jacob Presson, senior research analyst at Cutting Edge Information. "While managed markets teams typically lead this charge, other groups are often involved with getting products onto formularies."

At two out of three surveyed Top 50 companies, both market access and marketing are involved in formulary issues. Among small companies, team involvement ranges from a single group of managed markets personnel to a companywide effort involving regulatory, medical affairs, brand teams and marketing. Health economics and outcomes research (HEOR) groups and medical affairs teams are brought in for some products to make an effective pharmacoeconomics case regarding specific therapies.

"US Government Drug Reimbursement" is available at http://www.cuttingedgeinfo.com/research/market-access/us-government-drug-reimbursement/ and provides a roadmap for better navigating government drug reimbursement amidst the growing influence of the Affordable Care Act. The report, derived from primary resources and direct interviews, focuses exclusively on US government reimbursement strategies and trends, draws on quantitative and qualitative data from top-performing life science executives to provide actionable insights for winning and maintaining formulary position. Additional guidance outlined in the report includes:

  • Anticipating government payer needs and developing strong market access strategies
  • Managing payer relationships before and after product launches to maintain formulary position
  • Understanding compliant government reimbursement practices in the United States' new healthcare environment

To learn more about Cutting Edge Information and its research report offerings, please visit http://cuttingedgeinfo.com/.

Contact Information